-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Genmab, Raises Price Target to $52

Benzinga·10/26/2026 17:02:36
语音播报
TD Cowen analyst Yaron Werber maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $43 to $52.